期刊文献+

荧光原位杂交与免疫组化法检测乳腺癌HER-2表达的临床意义 被引量:3

Fluorescence in situ Hybridization and Immunohistochemistry in Detection of HER-2 for Breast Cancer
原文传递
导出
摘要 [目的]探讨乳腺癌中荧光原位杂交(FISH)检测HER-2基因的扩增和免疫组织化学(IHC)检测HER-2蛋白表达在临床诊断及分子靶向治疗中的应用。[方法]采用FISH与IHC检测50例乳腺癌组织中HER-2基因的扩增与HER-2蛋白表达。[结果]50例浸润性乳腺癌中,FISH检测HER-2基因扩增阳性15例(30%),IHC检测HER-2蛋白表达(-~+)40例,HER-2蛋白表达(++)的2例,HER-2蛋白表达(+++)的8例。[结论]FISH检测HER-2基因的扩增与IHC检测HER-2蛋白表达(++~+++)有较高的一致性。对于IHC检测HER-2(-~++)表达时,必须进一步FISH检测。
出处 《肿瘤学杂志》 CAS 2012年第4期306-308,共3页 Journal of Chinese Oncology
基金 卫生部科研基金资助项目(WKJ2007-3-001)
  • 相关文献

参考文献9

  • 1Ross JS,Gray GS. Targeted therapy for cancer:the HER2/ neu and Herceptin story [J]. Clin Eeadersh Manag Rev, 2003,176(6) : 333-340.
  • 2Press MF,Sauter G,Bernstein L,et al. Diagnostic evalua- tion of HER-2 as a molecular target:an assessment of ac- curacy and repyodcibility of laboratory testing in large, prospective, randmized clinical trials[J]. Clin Cancer Res, 2005,11 (18) : 6598-6607.
  • 3<乳腺癌HER2检测指南>编写组,霍临明.乳腺癌HER2检测指南[J].中华病理学杂志,2006,35(10):631-633. 被引量:164
  • 4王涛,江泽飞,宋三泰,刘晓晴,于静新,刘芳,闫敏.单药赫赛汀~治疗复发转移性乳腺癌[J].中华肿瘤杂志,2004,26(7):430-432. 被引量:25
  • 5Romond EH,Perez EA,Bryant J,et al. Trastuzumab plus adjuvaht chemotherapy for operable HER2 positive breast cancer[J]. Engl J Med,2005,353(16) : 1659-1672.
  • 6Hicks DG,Tubbs RR. Assessment of the HER2 status in breast cancer by fluorescence in situ hybridization a tech- nical review with interpretive guidelines [J]. Hum Pathol, 2005,36:250-261.
  • 7Cell Markers and Cytogenetics Committees College of American Pathologists. Clinical laboratory assays for HER2/neu amplification and overexpression: quality assur- ance, standardization, and proficiency testing [J]. Arch Pathol Lab Med, 2002,126(7):803-808.
  • 8郭华雄,邓明凤,陈登峰,张柳,袁璐,刘静,杨勇,徐正丰,王昌富.FISH和IHC检测HER2基因及蛋白在乳腺癌诊治中的应用[J].中国组织化学与细胞化学杂志,2010,19(4):353-356. 被引量:4
  • 9吕亚莉,钟梅,刘琳,赵坡.335例乳腺癌HER-2基因扩增及17号染色体多体的临床病理学分析[J].诊断病理学杂志,2008,15(3):169-173. 被引量:16

二级参考文献51

共引文献204

同被引文献58

  • 1中国癌症防治办公室,中国抗癌协会.中国常见恶性肿瘤诊治规范[M].北京:北京医科大学、中国协和医科大学联合出版社,1990:10.
  • 2蒙彦军.乳腺癌发病现况的研究进展[J].中国药物经济学,2013(3):440.441.
  • 3Soda M,Choi YL,Enomoto M. Identification of the transforming EML4-ALK fusion gene in non-small cell lung cancer[J].Nature,2007,(7153):561-566.
  • 4Lin E,Li L,Guan Y. Exon array profiling detects EML4-ALK fusion in breast,colorectal,and non-small cell lung cancers[J].Molecular Cancer Research,2009,(09):1466-1476.
  • 5Takeuchi K,Choi YL,Togashi Y. KIF5B-ALK,a novel fusion oncokinase identified by an immunohistochemistry-based diagnostic system for ALK-positive lung cancer[J].Clinical Cancer Research,2009,(09):3143-3149.doi:10.1158/1078-0432.CCR-08-3248.
  • 6Takeuchi K,Choi YL,Soda M. Multiplex reverse transcription-PCR screening for EML4-ALK fusion transcripts[J].Clinical Cancer Research,2008,(20):6618-6624.doi:10.1158/1078-0432.CCR-08-1018.
  • 7Fukuyoshi Y,Inoue H,Kita Y. EML4-ALK fusion transcript is not found in gastrointestinal and breast cancers[J].British Journal of Cancer,2008,(09):1536-1539.
  • 8Mino-Kenudson M,Chirieac LR,Law K. A novel highly sensitive antibody allows for theroutine detection of ALK-rearranged lung adenocarcinomas by standard immunohistoehemist[J].Clinical Cancer Research,2010,(05):1561-1571.
  • 9Zhang X,Zhang S,Yang X. Fusion of EML4 and ALK is associated with development of lung adenocarcinomas lacking EGFR and KRAS mutation and is correlated with ALK expression[J].Molecular Cancer Therapeutics,2010.188.
  • 10Sasaki T,Rodig SJ,Chirieac LR. The biology and treatment of EML4-ALK non-small cell lung cancer[J].European Journal of Cancer,2010,(10):1773-1780.

引证文献3

二级引证文献4

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部